- Tytuł:
- Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
- Autorzy:
- Źródło:
- In The Lancet 21-27 November 2015 386(10008):2078-2088
Czasopismo naukowe